Date: 2017-12-06
Type of information: Nomination
Compound: chief medical officer
Company: Tapimmune (USA - FL)
Therapeutic area: Cancer - Oncology
Type agreement: nomination
Action mechanism:
Disease:
Details:
- • On December 6, 2017, TapImmune announced the appointment of Richard Kenney, as Acting Chief Medical Officer. In this newly created role at TapImmune, Dr. Kenney will continue to manage the company’s ongoing and planned clinical programs for its novel, multi-epitope, T-cell vaccine candidates. Dr. Kenney has served as Head of Clinical Development for TapImmune since May 2017, and served previously as Chief Medical Officer for two biotech publicly traded companies focused on developing immunotherapies for oncology and infectious disease.
- Dr. Kenney also serves as President of ClinReg Biologics, his own clinical consulting firm. Prior to this role, Dr. Kenney served as Principal Medical Advisor and Chief Medical Officer of Immune Design, where he led the clinical development, pharmacovigilance and regulatory affairs groups to advance the development and commercialization of the company’s prime-boost immunotherapeutic vaccines. Previously, Dr. Kenney served as Chief Medical Officer of Crucell Holland, where he directed the development of a broad platform of vaccines, and as Senior Vice President, Clinical Development for Vical Incorporated, where he led the clinical development of DNA vaccines for cancer immunotherapy and infectious diseases. Dr. Kenney held key positions in vaccine development at GSK Biologicals from 2005 to 2009, most recently as Senior Director of Global Clinical R&D, Vaccines for Viral Diseases. He earned his M.D. degree at Harvard Medical School, then completed his residency in Internal Medicine at Duke University Medical Center and a fellowship in Infectious Diseases at the National Institute of Allergy and Infectious Diseases.
Financial terms:
Latest news:
Is general: Yes
